Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Méndez-Vidal, María José
• dc.contributor.author Molina, Áurea
• dc.contributor.author Anido, Urbano
• dc.contributor.author Chirivella, Isabel
• dc.contributor.author Etxaniz, Olatz
• dc.contributor.author Fernández-Parra, Eva
• dc.contributor.author Guix Arnau, Marta, 1974-
• dc.contributor.author Hernández, Carolina
• dc.contributor.author Lambea, Julio
• dc.contributor.author Montesa, Álvaro
• dc.contributor.author Pinto, Álvaro
• dc.contributor.author Ros, Silverio
• dc.contributor.author Gallardo, Enrique
• dc.date.accessioned 2019-03-13T09:20:06Z
• dc.date.available 2019-03-13T09:20:06Z
• dc.date.issued 2018
• dc.description.abstract BACKGROUND: Pazopanib is indicated in the first-line treatment of metastatic renal cell cancer (mRCC). The aim of this study was to review the efficacy, safety, and pharmacokinetics of pazopanib and see how these aspects are linked to clinical practice. METHODS: A non-exhaustive systematic review was conducted according to the three topics. No publication restrictions were imposed and the selected languages were Spanish and English. After that, a summary of the main results and findings of the review was presented and discussed during three meetings (one for each topic) with 13 medical oncologists that usually treat mRCC. At these meetings, a questionnaire on the first-line use of pazopanib in clinical practice was also drawn up. After the meetings, the questionnaire was completed by 60 specialist medical oncologists in renal cancer. RESULTS: The efficacy and safety of pazopanib have been demonstrated in several clinical trials, and subsequently confirmed in studies in real-world clinical practice. In addition to its clinical benefit and good safety profile, quality of life results for pazopanib, which compare favorably to sunitinib, make it a good option in the first-line treatment of patients. Special populations have been included in studies conducted with pazopanib, and it is safe for use in elderly patients, poor functional status, kidney failure, and mild or moderate hepatic impairment, and in patients with concomitant cardiovascular disease. The results of the questionnaire have shown that pazopanib is perceived as an effective drug, in which quality of life (QoL) outcomes are valued above all. CONCLUSIONS: This paper offers a comprehensive and critical summary of efficacy, tolerability, and pharmacokinetics of pazopanib in the treatment of mRCC. Pazopanib is an effective treatment with an acceptable safety profile. Its QoL and tolerability results offer certain advantages when compared with other therapeutic alternatives, and its use appears to be safe in different patient profiles
• dc.format.mimetype application/pdf
• dc.identifier.citation Méndez-Vidal MJ, Molina Á, Anido U, Chirivella I, Etxaniz O, Fernández-Parra E. et al. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma. BMC Pharmacol Toxicol. 2018 Nov 26;19(1):77. DOI: 10.1186/s40360-018-0264-8
• dc.identifier.doi http://dx.doi.org/10.1186/s40360-018-0264-8
• dc.identifier.issn 2050-6511
• dc.identifier.uri http://hdl.handle.net/10230/36808
• dc.language.iso eng
• dc.publisher BioMed Central
• dc.relation.ispartof BMC Pharmacology and Toxicology. 2018 Nov 26;19(1):77
• dc.rights © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Antineoplastic agents
• dc.subject.keyword Carcinoma
• dc.subject.keyword Renal cell
• dc.subject.keyword Kidney neoplasms
• dc.subject.keyword Pazopanib
• dc.subject.keyword Protein kinase inhibitors
• dc.subject.keyword Quality of life
• dc.subject.other Ronyons -- Càncer
• dc.subject.other Qualitat de vida
• dc.title Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion